Methods and compositions for monitoring and risk prediction...

Details Methods and compositions for monitoring and risk prediction... Methods and compositions for monitoring and risk prediction...

2007-11-14

2010-11-30

Cook, Lisa V (Department: 1641)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S004000, C435S007100, C435S174000, C436S501000, C436S518000

Reexamination Certificate

active

07842472

ABSTRACT:
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.

REFERENCES:
patent: 4900662 (1990-02-01), Shah et al.
patent: 5202234 (1993-04-01), Shah et al.
patent: 5382515 (1995-01-01), Shah et al.
patent: 5382522 (1995-01-01), Shah et al.
patent: 5480792 (1996-01-01), Buechler et al.
patent: 5525524 (1996-06-01), Buechler et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5631171 (1997-05-01), Sandstrom et al.
patent: 5679526 (1997-10-01), Buechler et al.
patent: 5763189 (1998-06-01), Buechler et al.
patent: 5795725 (1998-08-01), Buechler et al.
patent: 5824799 (1998-10-01), Buechler et al.
patent: 5843690 (1998-12-01), Gargan
patent: 5851776 (1998-12-01), Valkirs
patent: 5885527 (1999-03-01), Buechler
patent: 5922615 (1999-07-01), Nowakowski et al.
patent: 5939272 (1999-08-01), Buechler et al.
patent: 5947124 (1999-09-01), Buechler et al.
patent: 5955377 (1999-09-01), Maul et al.
patent: 5985579 (1999-11-01), Buechler et al.
patent: 6019944 (2000-02-01), Buechler
patent: 6057098 (2000-05-01), Buechler et al.
patent: 6113855 (2000-09-01), Buechler et al.
patent: 6143576 (2000-11-01), Buechler
patent: 6156521 (2000-12-01), Buechler et al.
patent: 6174686 (2001-01-01), Buechler et al.
patent: 6238931 (2001-05-01), Buechler et al.
patent: 6251687 (2001-06-01), Buechler et al.
patent: 6316409 (2001-11-01), Neri et al.
patent: 6579687 (2003-06-01), Buechler et al.
patent: 6627404 (2003-09-01), Buechler et al.
patent: 6939678 (2005-09-01), Buechler et al.
patent: 6991907 (2006-01-01), Buechler et al.
patent: 7341838 (2008-03-01), Buechler et al.
patent: 7358055 (2008-04-01), Valkirs et al.
patent: 7361473 (2008-04-01), Valkirs et al.
patent: 7427490 (2008-09-01), Valkirs et al.
patent: 2003/0022235 (2003-01-01), Dahlen et al.
patent: 2003/0119064 (2003-06-01), Valkirs et al.
patent: 2003/0199000 (2003-10-01), Valkirs et al.
patent: 2003/0211544 (2003-11-01), Buechler et al.
patent: 2003/0219734 (2003-11-01), Buechler
patent: 2004/0121343 (2004-06-01), Buechler et al.
patent: 2004/0121350 (2004-06-01), Anderberg et al.
patent: 2004/0126767 (2004-07-01), Anderberg et al.
patent: 2004/0171064 (2004-09-01), Dahlen et al.
patent: 2004/0176914 (2004-09-01), Buechler et al.
patent: 2004/0203083 (2004-10-01), Buechler et al.
patent: 2004/0209307 (2004-10-01), Valkirs et al.
patent: 2004/0219509 (2004-11-01), Valkirs et al.
patent: 2004/0219603 (2004-11-01), Devarajan et al.
patent: 2004/0253637 (2004-12-01), Buechler et al.
patent: 2005/0148024 (2005-07-01), Buechler
patent: 2005/0164317 (2005-07-01), Buechler et al.
patent: 2005/0255484 (2005-11-01), Valkirs et al.
patent: 2006/0051825 (2006-03-01), Buechler et al.
patent: 2006/0105419 (2006-05-01), Blankenberg et al.
patent: 2007/0092911 (2007-04-01), Buechler et al.
patent: 2007/0196880 (2007-08-01), Buechler et al.
patent: 2007/0218498 (2007-09-01), Buechler et al.
patent: 2007/0224643 (2007-09-01), McPherson et al.
patent: 2007/0269836 (2007-11-01), McPherson
patent: 2008/0045444 (2008-02-01), Whittaker
patent: 2008/0050832 (2008-02-01), Buechler et al.
patent: 2008/0118924 (2008-05-01), Buechler
patent: 2008/0293920 (2008-11-01), Buechler
patent: 2009/0061467 (2009-03-01), Buechler et al.
patent: WO 93/24231 (1993-12-01), None
patent: WO 95/08772 (1995-03-01), None
patent: WO 98/08606 (1998-03-01), None
patent: WO 98/21563 (1998-05-01), None
patent: WO 98/08606 (1998-07-01), None
patent: WO 98/43739 (1998-10-01), None
patent: WO 98/43739 (2001-06-01), None
patent: WO 2004/058055 (2004-07-01), None
patent: WO 2004/058055 (2004-07-01), None
patent: WO 2004/059293 (2004-07-01), None
patent: WO 2004/088276 (2004-10-01), None
patent: WO 2004/088276 (2004-11-01), None
patent: WO 2004/059293 (2005-03-01), None
patent: WO 2005/121788 (2005-12-01), None
patent: WO 2005/121788 (2005-12-01), None
patent: WO 2006/066587 (2006-06-01), None
patent: WO 2008/061149 (2008-05-01), None
patent: WO 2008/061149 (2008-10-01), None
Bachorzewska, et al. Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography. Nephrol. Dial. Transplant. 2007;(22):295-296.
Boerrigter, et al. Des-Serine-Proline B-Type Natriuretic Peptide (BNP 3-32) in Cardiorenal Regulation. Am J Physiol Regul Integr Comp Physiol (Oct. 26, 2006).
Cataliotti, et al. Circulating Natriuretic Peptide Concentrations in Patients with End-Stage Renal Disease: Role for Brain Natriuretic Peptide as a Biomarker for Ventricular Remodeling. Mayo Clin. Proc. 2001;76:1111-1119.
Chen et aI. The Natriuretic Peptides in Heart Failure: Diagnostic and Therapeutic Potentials. Proceedings of the Assoc of American Physicians. Sep./Oct. 1999; 111(5):406-416.
Dangas et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. Jan. 1, 2005;95(1):13-9.
Davis et al. Genomic based biomarkers of drug-induced nephrotoxicity. Expert Opin Drug Metab Toxicol. Feb. 2006;2(1):95-101.
Fischer et al. Uncomplicated acute renal failure and hospital resource utilization: a retrospective multicenter analysis. Am J Kidney Dis. Dec. 2005;46(6):1049-57.
Francis, G. Acute decompensated heart failure; the cardiorenal syndrome. Cleve Clin J Med. Jun. 2006;73 Suppl 2:S8-13; discussion S30-3.
Gruberg et al. The prognostic implications of further renal function deterioration within 48 hours of interventional coronary procedures in patients with pre-existent chronic renal insufficiency.J Am Coll Cardiol. Nov. 1, 2000;36(5):1542-8.
Mahon et al. Perioperative acute renal failure. Curr Opin Anaesthesiol. Jun. 2006;19(3):332-8.
Mccullough et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol. Sep. 18, 2006;98(6A):27K-36K.
Mccullough P.A. Beyond Serum Creatinine: Defining the Patient with Renal Insufficiency and Why? Reviews in Cardiovascular Medicine. 2003; 4(1): 82-86.
Mehran et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. Oct. 6, 2004;44(7):1393-9.
Ok et al. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney International. 1995; 68:173-78.
Permberton, et al. Deconvolution Analysis of Cardiac Natriuretic Peptides During Acute Volume Overload. Hypertension. Sep. 2000; 355-359.
Persson et al. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. Jul. 2005;68(1):14-22.
Persson, PB. Contrast-induced nephropathy. Eur Radiol. Nov. 2005;15 Suppl 4:D65-9.
Schneider et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol. Nov. 1, 2006;164(9):881-9.
Sharma et al. TGF-β in diabetic kidney disease: role of novel signaling pathways. Cytokine Growth Factor Rev. Mar.-Jun. 2000;11(1-2):115-23.
Shur, B. The receptor function of galactosyltransferase during cellular interactions. Mol Cell Biochem. 1984;61(2):143-58.
Simpson, D. Controversies in the estimation of glomerular filtration rate. Nucl Med Commun. Apr. 2006;27(4):407.
Stacul et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. Sep. 18, 2006;98(6A):59K-77K.
Taber et al. Drug-Associated Renal Dysfunction. Crit Care Clin. Apr. 2006;22(2):357-74, viii.
U.S. Appl. No. 60/436,392, filed Dec. 24, 2002, Anderberg et al.
Anderson, L. Candidate-Based Proteomics in the Search for Biomarkers of Cardiovascular Disease. J. Physio

Affiliated with

Also associated with

Rating

Methods and compositions for monitoring and risk prediction... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for monitoring and risk prediction..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for monitoring and risk prediction... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4191623